BioMarin (BMRN) Q2 2026 Earnings
How Did BMRN Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: −1.40%.
Did BMRN Beat Earnings? Q2 2026 Results
Yes. BioMarin reported Q2 2026 earnings of $1.20 a share on Aug 6, 2026, beating the $0.95 consensus estimate by 25.8%. Revenue was $989.7M against a $932.0M estimate.
BioMarin delivered a strong second quarter for fiscal 2026, posting revenue of $989.71 million, a 19.9% year-over-year gain that cleared the $932.04 million consensus estimate by 6.19%, while adjusted diluted EPS of $1.20 beat the $0.95 analyst expectation by 25.76%. The primary engine behind the revenue acceleration was the April 2026 close of the Amicus Therapeutics acquisition, which folded GALAFOLD and POMBILITI + OPFOLDA into BioMarin's portfolio alongside continued momentum in VOXZOGO and PALYNZIQ. The integration is already yielding identified cost synergies of approximately $220 million on a non-GAAP basis, targeted for full realization by 2028. Management followed the strong print by lifting full-year 2026 revenue guidance to $3.88 billion to $3.93 billion and raising non-GAAP diluted EPS guidance to $4.90 to $5.10, a midpoint reflecting roughly 59% year-over-year growth. Adding further strategic dimension, BioMarin's subsequent acquisition of Alesta Therapeutics sent shares up sharply in premarket trading, signaling continued investor appetite for the company's rare-disease expansion.
- Acquisition of Amicus Therapeutics adding GALAFOLD and POMBILITI + OPFOLDA revenues
- New patient initiations for VOXZOGO across all regions, with global patients on therapy growing more than 20% Y/Y
- Growth in U.S. patients treated with PALYNZIQ, with 27% Y/Y revenue growth
- Metabolic Conditions revenue grew 25% Y/Y driven by acquired products and PALYNZIQ strength
- VIMIZIM revenue declined 10% due to timing of large government orders outside U.S.
- ALDURAZYME revenue declined 21% due to timing of order fulfillment to Sanofi
“This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA, and extending the benefit of these medicines to more patients worldwide.”
BioMarin CEO, on the earnings call
What Is BioMarin's Outlook?
BioMarin raised full-year 2026 guidance: Total Revenues now expected at $3,875M–$3,925M (from $3,825M–$3,925M), with midpoint Y/Y growth of 21%. VOXZOGO revenue guidance raised to $1,000M–$1,050M (from $975M–$1,025M). Metabolic Conditions revenue unchanged at $2,725M–$2,775M. Non-GAAP Diluted EPS guidance raised to $4.90–$5.10 (from $4.85–$5.05), representing 59% midpoint Y/Y growth. The company expects annualized interest expense of approximately $200M from Amicus financing. GALAFOLD and POMBILITI + OPFOLDA combined are expected to reach over 60% Non-GAAP Operating Margin by 2030, with peak revenues of approximately $1.4B and $1.2B, respectively, by the mid-2030s. Gross leverage is targeted below 2.5x by mid-2027.
BMRN YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $989.7M | $825.4M | +19.9% |
| Gross Profit | $786.9M | $675.3M | +16.5% |
| Operating Income | $110.9M | $276.9M | −59.9% |
| Net Income | $44.8M | $240.5M | −81.4% |
BMRN Revenue by Segment
When Does BioMarin Report Next?
Figures from SEC filings and company reports. Not investment advice.